- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06023784
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
September 3, 2023 updated by: Peking Union Medical College Hospital
The Impact of Left Bundle Branch Area Pacing Versus Right Ventricular Pacing on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block: a Randomized Controlled Trial
This is a single-center, randomized controlled study.
The aim of this study is to compare the impact of left bundle branch area pacing versus traditional right ventricular pacing on the incidence of atrial fibrillation in patients with atrioventricular block.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
530
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Deyan Yang, PhD.
- Phone Number: +86 (010)69155068
- Email: swallow_sums@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital
-
Contact:
- Deyan Yang, PhD.
- Phone Number: +86 (010)69155068
- Email: swallow_sums@163.com
-
Contact:
- Taibo Chen, PhD.
- Phone Number: +86 (010)69155068
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Adult patients aged 18-85;
- AV block patients with ventricular pacing indications and the expected rate of ventricular pacing(VP)> 40%, including (a) third-degree AV block; (b) second degree AV block (type II); (c) intermittent advanced AV block with expected VP>40%; (d) symptomatic first degree AV block and PR interval on ECG > 300ms;
- Signed informed consent;
Exclusion Criteria:
- Baseline echocardiographic assessment of patients with impaired LV function (LVEF<50%);
- Patients with the history of atrial fibrillation;
- Having difficulties in follow-up: Those who cannot accept 2-year follow-up on time due to physical condition or other reasons;
- Pacemaker replacement without new implanted ventricular electrodes;
- Surgery is required within 1 year due to severe structural heart disease;
- Patients with tricuspid mechanical valve replacement, or congenital heart disease (including transposition of the great arteries, or permanent left superior vena cava, etc);
- AV block resulting from: (a) Hypertrophic cardiomyopathy(HCM), (b) ventricular septal defect repair, and those who are unlikely to achieve successful LBBAP procedure.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: left bundle branch area pacing
|
Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing.
In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
|
|
Active Comparator: right ventricular pacing
|
Right ventricular pacing is the traditional pacing modality for ventricular pacing.
The pacing lead was placed in the apex or septum of right ventricle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the incidence of new-onset atrial fibrillation
Time Frame: within two years after device implantation
|
within two years after device implantation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
all-cause mortality
Time Frame: within two years after device implantation
|
within two years after device implantation
|
|
hospitalization for heart failure
Time Frame: within two years after device implantation
|
within two years after device implantation
|
|
an device upgrade for heart failure
Time Frame: within two years after device implantation
|
within two years after device implantation
|
|
alteration of quality of life score
Time Frame: within two years after device implantation
|
within two years after device implantation
|
|
Improvement of left ventricular, right ventricular and left atrial function measured by echocardiography
Time Frame: within two years after device implantation
|
within two years after device implantation
|
|
pacemaker-associated cardiomyopathy
Time Frame: within two years after device implantation
|
within two years after device implantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Taibo Chen, PhD., Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 30, 2023
Primary Completion (Estimated)
December 31, 2028
Study Completion (Estimated)
December 31, 2030
Study Registration Dates
First Submitted
August 24, 2023
First Submitted That Met QC Criteria
September 3, 2023
First Posted (Actual)
September 5, 2023
Study Record Updates
Last Update Posted (Actual)
September 5, 2023
Last Update Submitted That Met QC Criteria
September 3, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- the July study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.